Previous 10 | Next 10 |
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks T...
Platform Presentation to Include Initial Safety, Tolerability, and Pharmacokinetic Data from Ongoing Phase 1 Trials Neuroscience Presentation to Include Data from Preclinical Tau and Alpha-Synuclein Programs NEW HAVEN, Conn., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc., (Nasdaq...
NEW HAVEN, Conn., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced that six new thought leaders will join the company’s scientific advisory board (SAB). The new membe...
Bayer ( OTCPK:BAYZF ) and Arvinas (NASDAQ: ARVN ) say they have finalized the terms of their agreement to jointly launch a new company called Oerth Bio. More news on: Arvinas, Inc., Bayer Aktiengesellschaft, Healthcare stocks news, Merger & acquisition news, Read more ......
- Oerth Bio to utilize Arvinas’ PROTAC® technology to develop innovative new agricultural products to improve crop yields - John Dombrosky Announced as CEO of Oerth Bio - Transaction had been formally closed on July 15, 2019 MONHEIM, Germany and BOSTON and NEW HAVEN, ...
Arvinas (NASDAQ: ARVN ) initiated with Outperform rating and $38 (61% upside) price target at Wedbush. More news on: Arvinas, Inc., Minerva Neurosciences, Inc., Strongbridge Biopharma plc, Healthcare stocks news, Stocks on the move, , Read more ...
ANI Pharmaceuticals (NASDAQ: ANIP ) initiated with Buy rating and $76 (9% upside) price target at Guggenheim. More news on: ANI Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Arvinas (NASDAQ: ARVN ) initiates its second clinical program with the launch of a Phase 1 study assessing ARV-471 in patients with locally advanced/metastatic ER+/HER2- breast cancer. Preliminary data should be available in 2020. More news on: Arvinas, Inc., Healthcare stocks news, ...
NEW HAVEN, Conn., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the initiation of patient dosing in its second clinical program. The Phase 1 clinical trial of ARV-4...
NEW HAVEN, Conn. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the company is scheduled to present at the 2019 Wedbush PacGrow Healthcare Conference on W...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann...